{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:19:40Z","timestamp":1780571980615,"version":"3.54.1"},"reference-count":38,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82401026"],"award-info":[{"award-number":["82401026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital Young Reserve Talent Development Program","doi-asserted-by":"publisher","award":["UHB12595"],"award-info":[{"award-number":["UHB12595"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CMA Young and Middle-aged Doctors Outstanding Development Program-Osteoporosis Specialized Scientific Research Fund Project","award":["GX2021A01"],"award-info":[{"award-number":["GX2021A01"]}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2023-PT320-10"],"award-info":[{"award-number":["2023-PT320-10"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-014"],"award-info":[{"award-number":["2022-PUMCH-B-014"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Denosumab is approved for treating hypercalcemia of malignancy, but data on its efficacy for hypercalcemia related to primary hyperparathyroidism (PHPT) are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare the efficacy and safety of denosumab with zoledronic acid in PHPT-related hypercalcemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively collected data from 29 PHPT patients with moderate\/severe hypercalcemia (corrected serum calcium [CSC] \u2265 3.0 mmol\/L) treated with denosumab (60 or 120 mg; Dmab group) and CSC-matched 29 PHPT patients treated with zoledronic acid (4 mg; ZA group). The primary efficacy outcome was the change of CSC (\u0394Ca), while secondary outcomes included the response proportion, time to response, and duration of response. Safety data were also collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Both groups showed significant reductions in CSC levels (Dmab: 3.37 \u00b1\u202f0.37 mmol\/L to 2.64 \u00b1 0.33 mmol\/L, \u202f P &amp;lt;\u202f.01; ZA: 3.41 \u00b1 0.32 mmol\/L to 2.57 \u00b1 0.23 mmol\/L, P\u202f&amp;lt; .01), with similar \u0394Ca. In the Dmab group, 82.8% (24\/29) responded with CSC levels below 3.0 mmol\/L, and 72.4% (21\/29) achieved complete response (CR, serum CSC less than 2.7 mmol\/L), comparable to the ZA group. The time to CR was shorter for ZA (3.0 vs 7.0 days, P &amp;lt; .01), while Dmab had a longer duration of response (19.0 vs 13.0 days, P = .02). Hypocalcemia occurred in 6.9% (2\/29, both with chronic kidney disease stage 3b) of Dmab patients, while none in the ZA group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A single 60-mg dose of denosumab effectively reduces serum calcium levels in PHPT patients with moderate\/severe hypercalcemia, at least maintaining efficacy for a median of nearly 3 weeks without serious adverse events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf107","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:17:16Z","timestamp":1741115836000},"page":"e3756-e3767","source":"Crossref","is-referenced-by-count":5,"title":["The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6572-1827","authenticated-orcid":false,"given":"An","family":"Song","sequence":"first","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-1464","authenticated-orcid":false,"given":"Yingyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3759-4984","authenticated-orcid":false,"given":"Rong","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Kou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6805-1611","authenticated-orcid":false,"given":"Jiajia","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Nie","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-3462","authenticated-orcid":false,"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8634-2252","authenticated-orcid":false,"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":false,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2759-5177","authenticated-orcid":false,"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0395-8789","authenticated-orcid":false,"given":"Ou","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"16","key":"2025101519582354500_dgaf107-B1","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: a review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"2025101519582354500_dgaf107-B2","first-page":"1959","article-title":"A practical approach to hypercalcemia","volume":"67","author":"Carroll","year":"2003","journal-title":"Am Fam Physician"},{"issue":"8","key":"2025101519582354500_dgaf107-B3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2025101519582354500_dgaf107-B4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0b013e31824be20e","article-title":"Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis","volume":"36","author":"Sun","year":"2013","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"2025101519582354500_dgaf107-B5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025101519582354500_dgaf107-B6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an endocrine society clinical practice guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"35","key":"2025101519582354500_dgaf107-B7","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025101519582354500_dgaf107-B8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","article-title":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"51","author":"Diel","year":"2015","journal-title":"Eur J Cancer"},{"issue":"12","key":"2025101519582354500_dgaf107-B9","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2020.0538","article-title":"Diagnosis and management of primary hyperparathyroidism","volume":"323","author":"Zhu","year":"2020","journal-title":"JAMA"},{"key":"2025101519582354500_dgaf107-B10","doi-asserted-by":"crossref","first-page":"1027598","DOI":"10.3389\/fendo.2023.1027598","article-title":"Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a Chinese cohort","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2025101519582354500_dgaf107-B11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5694\/mja12.11243","article-title":"Resistant hypercalcaemia in metastatic parathyroid carcinoma","volume":"198","author":"Bowyer","year":"2013","journal-title":"Med J Aust"},{"issue":"3","key":"2025101519582354500_dgaf107-B12","doi-asserted-by":"crossref","first-page":"L7","DOI":"10.1530\/EJE-14-0482","article-title":"Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma","volume":"171","author":"Nadarasa","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025101519582354500_dgaf107-B13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","author":"Vellanki","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025101519582354500_dgaf107-B14","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-14-0166","article-title":"Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab","volume":"171","author":"Karuppiah","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025101519582354500_dgaf107-B15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/qjmed\/hcu166","article-title":"Use of denosumab in parathyroid carcinoma with refractory hypercalcemia","volume":"108","author":"Tong","year":"2015","journal-title":"QJM"},{"issue":"2","key":"2025101519582354500_dgaf107-B16","first-page":"e141","article-title":"Denosumab for the treatment of refractory hypercalcemia in metastatic parathyroid carcinoma","volume":"1","author":"Itoshima","year":"2015","journal-title":"AACE Clin Case Rep"},{"issue":"5","key":"2025101519582354500_dgaf107-B17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4158\/EP14410.OR","article-title":"The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia","volume":"21","author":"Fountas","year":"2015","journal-title":"Endocr Pract"},{"issue":"1","key":"2025101519582354500_dgaf107-B18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/qjmed\/hcw206","article-title":"Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia","volume":"110","author":"Fountas","year":"2017","journal-title":"QJM"},{"key":"2025101519582354500_dgaf107-B19","first-page":"150082","article-title":"Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy","volume":"2015","author":"Jumpertz von Schwartzenberg","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"2025101519582354500_dgaf107-B20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcrpr.2018.01.002","article-title":"Refractory hypercalcemia due to hyperparathyroidism in a patient with metastatic parathyroid carcinoma","volume":"5","author":"Hsu","year":"2018","journal-title":"J Cancer Res Pract"},{"issue":"2","key":"2025101519582354500_dgaf107-B21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/ijem.IJEM_678_18","article-title":"Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction","volume":"23","author":"Rajan","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"2025101519582354500_dgaf107-B22","doi-asserted-by":"crossref","first-page":"e233665","DOI":"10.1136\/bcr-2019-233665","article-title":"Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia","volume":"13","author":"Li","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"10","key":"2025101519582354500_dgaf107-B23","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary hyperparathyroidism","volume":"9","author":"Eremkina","year":"2020","journal-title":"Endocr Connect"},{"issue":"1","key":"2025101519582354500_dgaf107-B24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/0896860819880095","article-title":"Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism","volume":"40","author":"Pratt","year":"2020","journal-title":"Perit Dial Int"},{"issue":"4","key":"2025101519582354500_dgaf107-B25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000510625","article-title":"Successful use of denosumab for life-threatening hypercalcemia in a pediatric patient with primary hyperparathyroidism","volume":"93","author":"Mamedova","year":"2020","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"2025101519582354500_dgaf107-B26","first-page":"669","article-title":"Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism","volume":"65","author":"Kuchay","year":"2021","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"2025101519582354500_dgaf107-B27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s42000-021-00343-w","article-title":"Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment","volume":"21","author":"Tzotzas","year":"2022","journal-title":"Hormones (Athens)"},{"key":"2025101519582354500_dgaf107-B28","doi-asserted-by":"crossref","first-page":"794988","DOI":"10.3389\/fendo.2021.794988","article-title":"Denosumab for the treatment of hypercalcemia in a patient with parathyroid carcinoma: a case report","volume":"12","author":"Roukain","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2025101519582354500_dgaf107-B29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00198-018-4688-1","article-title":"Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency","volume":"30","author":"Miyaoka","year":"2019","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025101519582354500_dgaf107-B30","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-023-03381-z","article-title":"Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency","volume":"81","author":"Gronskaya","year":"2023","journal-title":"Endocrine"},{"issue":"9","key":"2025101519582354500_dgaf107-B31","first-page":"729","article-title":"[The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis]","volume":"48","author":"Han","year":"2009","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"3","key":"2025101519582354500_dgaf107-B32","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EJE-12-0528","article-title":"Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature","volume":"168","author":"Witteveen","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025101519582354500_dgaf107-B33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00774-005-0680-x","article-title":"Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism","volume":"24","author":"Lee","year":"2006","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"2025101519582354500_dgaf107-B34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.14310\/horm.2002.1286","article-title":"Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid","volume":"9","author":"Corsello","year":"2010","journal-title":"Hormones (Athens)"},{"issue":"5","key":"2025101519582354500_dgaf107-B35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2025101519582354500_dgaf107-B36","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1002\/edm2.380","article-title":"Management of severe hypercalcaemia secondary to primary hyperparathyroidism: the efficacy of saline hydration, furosemide, and zoledronic acid","volume":"5","author":"Oueslati","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"issue":"6","key":"2025101519582354500_dgaf107-B37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00003495-200161060-00010","article-title":"Zoledronic acid","volume":"61","author":"Cheer","year":"2001","journal-title":"Drugs"},{"issue":"7","key":"2025101519582354500_dgaf107-B38","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf107\/62244347\/dgaf107.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/11\/e3756\/62244347\/dgaf107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/11\/e3756\/62244347\/dgaf107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:58:34Z","timestamp":1760572714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/11\/e3756\/8051154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,10,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf107","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,3,3]]}}}